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A B S T R A C T
Purpose: The aetiology of adult onset epilepsy remains unascertained in a signiﬁcant proportion of
patients. Antibodies directed against neuronal antigens have been suggested to have a potential
pathogenic role in some cases of epilepsy. We describe a series of patients with adult onset epilepsy in
whom antibodies to glutamic acid decarboxylase (GAD Abs) have been identiﬁed.
Methods: All patients attending a regional epilepsy service with unexplained adult onset epilepsy’ were
tested for the presence of GAD Abs. Those with high serum titres underwent CSF analysis, and were
offered additional treatment with immunotherapy. Those who underwent immunotherapy were
monitored by monthly review. Clinical details and response to treatment was collated by review of notes.
Results: Of 112 patients tested, high serum titres were found in 6 (5.4%) patients. These patients had
clinical and electroencephalographic evidence of focal epilepsy. CSF analysis revealed oligoclonal bands
and intrathecal GAD Abs in all patients. Five patients received immunotherapy. No improvement in
seizures was observed in any. One patient with equivocal MRI evidence of hippocampal sclerosis and
concordant video EEG and PET scan, achieved 12 months seizure freedom following temporal lobectomy.
Conclusions: The relevance of GAD Abs to epilepsy remains uncertain. Our experience does not support
the routine use of immunotherapy in patients with epilepsy and GAD Abs. Larger studies enrolling
greater numbers of patients are required to identify sufﬁcient numbers of patients for controlled
treatment trials.
 2014 Published by Elsevier Ltd on behalf of British Epilepsy Association.
Contents lists available at ScienceDirect
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A signiﬁcant number of patients develop epilepsy in adult life
despite identiﬁcation of epileptogenic abnormalities with brain
imaging techniques in only a proportion.1A large number of patients
with refractory epilepsy also have no identiﬁable structural brain
abnormalities.2 In recent years, a number of authors have reported
serum autoantibodies in patients with epilepsy directed against
neuronal cell surface antigens such as the voltage gated potassium
channel (VGKC) complex and the N-methyl-D-aspartate (NMDA)
glutamate receptor, as well as intracellular antigens such as
glutamic acid decarboxylase (GAD).3–7 Whilst these antibodies* Corresponding author at: Department of Neurology, Salford Royal Hospital NHS
Foundation Trust, Stott Lane, Salford M6 8HD, United Kingdom.
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1059-1311/ 2014 Published by Elsevier Ltd on behalf of British Epilepsy Association.have mainly been identiﬁed in patients with the clinical syndrome of
limbic encephalitis (LE), characterised by amnesia, encephalopathy
or change in affect and seizures, often in association with brain
imaging abnormalities,8–10 they are also found in patients with
seizures alone.4,11 This raises the possibility of an autoimmune
aetiology in some patients with otherwise unexplained epilepsy.
Favourable responses to immunotherapy have been observed in
patients with other neurological conditions, particularly where
associated with antibodies directed against neuronal cell surface
antigens.12–14 Immunotherapy may have a role in the treatment of
patients with epilepsy, particularly when autoantibodies directed
against neuronal cell surface antigens are found.9,15
GAD is the principal enzyme that catalyses the decarboxylation
of the neurotransmitter glutamic acid to gamma-aminotobutyric
acid (GABA). Antibodies directed against GAD (GAD Abs) have been
found in patients with a number of neurological conditions
including stiff person syndrome, cerebellar ataxia, limbic enceph-
alitis, myoclonus and in patients with epilepsy alone.16 Some
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person syndrome and suggested a shared aetiology in such
cases.6,17 In patients with epilepsy and GAD Abs the use of
immunotherapy has been attempted, with beneﬁcial effect
observed in some cases.7,18 In this setting, the presence of
intrathecal GAD Abs has been suggested as evidence of pathoge-
nicity.7
Since January 2010, we have tested all adult patients attending
our epilepsy service with ‘unexplained adult onset epilepsy’ for the
presence of serum GAD Abs, VGKC-complex antibodies and NMDA
receptor antibodies. We have previously reported the diagnostic
yield for VGKC complex antibody testing and response to
immunotherapy.5 We describe a cohort of patients with ‘unex-
plained adult onset epilepsy’ in whom GAD Abs were detected.
2. Methods
We reviewed the medical notes up to January 2013 of patients
with ‘unexplained adult onset epilepsy’ seen between January
2010 and December 2011 in tertiary epilepsy clinics in two
hospitals in Greater Manchester, UK, who had been tested for the
presence of serum GAD Abs. ‘Unexplained adult onset epilepsy’
was deﬁned as focal or unclassiﬁed epilepsy with onset in adult life
with no history of antecedent cerebral insults and no epileptogenic
lesions identiﬁed on MRI scanning using appropriate imaging
protocols. Patients with clearly deﬁned idiopathic generalised
epilepsy syndromes, symptomatic epilepsies and patients with the
either the clinical syndrome of LE or MRI evidence of inﬂammation
were not included.
All sera were tested using the clinical service at the
neuroimmunology laboratory at the University of Oxford using
the Ria-RSR (radioimmunoassay) GADAb assay (RSR Ltd, Cardiff,
UK) prior to September 2011 and the Elisa-RSR (ELISA) GADAb
assay (RSR Ltd, Cardiff, UK) after this date. Samples were sent to the
laboratory over the study period, and not tested as a single batch. A
positive result was deﬁned by the detection of GAD Abs at any
concentration within the tested sera. We then categorised positive
results from the Ria-RSR assay as either ‘low positive’ (1–1000 u/
mL) or ‘high positive’ (>1000 u/mL). This categorisation was based
on previous local experience and other studies which have
demonstrated a similar prevalence of low positive GAD Ab titres
in both epilepsy and control groups.3,7 We have assumed therefore
that the presence of GAD Abs at titres <1000 u/mL are not of
clinical signiﬁcance in this setting. Due to the different methodol-
ogy used with the Elisa-RSR assay, results are not directly
comparable with the Ria-RSR assay results and we deﬁned a
different cut off value for ‘low’ and ‘high’ positive results (5–
50 000 U/mL and >50 000 U/mL, respectively).
As well as testing for GAD Abs, patients meeting the same
inclusion criteria were also tested for VGKC complex antibodies
and NMDA receptor antibodies. These results are not discussed
further in this paper. Testing for other autoantibodies such as
GABA-b and AMPA was not performed as these assays were not
clinically available on a routine basis during the study period and
because previous studies had focussed on VGKC complex, NMDA
receptor and GAD Abs in patients with epilepsy.3
Patients found to have high positive GAD Ab titres were
investigated further with lumbar puncture and cerebrospinal ﬂuid
(CSF) analysis as part of routine clinical evaluation in an effort to
deﬁne the pathogenic relevance of the detected antibodies. These
patients were offered treatment with immunotherapy in addition
to standard treatment at the discretion of the treating physician.
In patients with high positive GAD Ab titres, demographic
information was collected and clinical details, investigation results
and response to treatment was observed and documented atmonthly review by one of the authors and collated retrospectively
by review of clinical records.
3. Results
During the study period 112 patients were tested for the
presence of serum GAD Abs. 14 (12.5%) were found to be positive.
Of these 6 (5.4%) patients had high positive serum GAD Ab titres.
The clinical characteristics of these patients are summarised in
Table 1. Eight remaining patients (7.1%) had low positive GAD Ab
titres. These patients were not retested and will not be discussed
further in this paper.
All patients with high positive GAD Ab titres were female, with
a mean age of 35 years (range 20–44). Four of the six patients had
other autoimmune diseases, including one patient with type 1
diabetes.
All six patients had focal seizures with clinical localisation of
the seizure focus to the temporal lobe in ﬁve patients. In one
remaining patient the clinical localisation of the seizure focus was
uncertain. Five patients also experienced generalised tonic clonic
seizures at some point since the onset of epilepsy. The median time
from onset of epilepsy to antibody testing was 9.5 years (range
1.25–23) and all patients were already receiving appropriate
antiepileptic drug (AED) treatment.
All patients had lumbar puncture following identiﬁcation of
high positive serum GAD Ab titres. Biochemical and microbiolog-
ical parameters were within normal limits apart from a slightly
raised CSF protein in one patient (Patient C, 0.52 g/L). GAD Abs
were detected in the CSF of all patients. Oligoclonal bands were
present in the CSF and unmatched in the serum in all patients. One
patient also had additional matching bands in the CSF and serum.
All of the patients had epilepsy protocol MRI imaging of the
brain prior to antibody testing. In all cases this was reported as
normal by a consultant neuroradiologist. In Patient A, subsequent
review during follow up, and further imaging with FDG-PET as part
of an epilepsy surgery workup revealed left mesial temporal
hypometabolism suggestive of mesial temporal sclerosis. We have
not excluded this patient from the analysis as at the point of entry
into the study the inclusion criteria were met. Extra-cranial
imaging was not performed in any patient.
Routine and prolonged EEG recordings captured focal slow
waves, and sharp and slow wave complexes in all patients. Video
telemetry (VT) evaluation was performed in all patients. Seizure
semiology, interictal and ictal EEG patterns and seizure classiﬁca-
tions are summarised in Table 2. Typical attacks were recorded
during VT in three of six patients, all of whom were conﬁrmed to
have focal epilepsy. The semiology included features suggestive of
temporal lobe onset, but in two of the three patients additional
seizures, likely to be of extra-temporal origin were also captured.
In Patient A, all seizures captured were of left mesial temporal
origin. This patient was subsequently entered into the epilepsy
surgery programme. No seizures were captured in three patients,
but focal interictal abnormalities were recorded in all.
At the point of antibody testing, all six patients were
experiencing ongoing seizures despite appropriate AED therapy.
Additional immunotherapy was received by ﬁve of the six patients
with high positive serum GAD Ab titres, GAD Abs detected in the
CSF and oligoclonal bands detected in the CSF unmatched in serum,
with the assumption that epilepsy in these patients may be of an
autoimmune aetiology and with the objective of improving seizure
control. Of these ﬁve patients, four received intravenous methyl-
prednisolone (IVMP) followed by oral prednisolone. IVMP was
administered at a dose of 1 g per day for 3 days. Oral prednisolone
was commenced at 1 mg/kg/day and tapered at the discretion of
the treating physician. All patients had stopped prednisolone by 12
weeks.
Table 1
Clinical characteristics of patients with epilepsy and high positive (>1000u/mL) GAD Ab titres.
Age,
Sex
Seizure type
and epilepsy
syndrome
Duration of
epilepsy at
antibody
testing
AED’s used
prior to
immunotherapy
Seizure frequency
at time of
antibody testing
Other
autoimmune
disorders
Serum
anti-GAD
titre (u/mL)
Cerebrospinal
ﬂuid analysis
CSF anti-GAD
titre (m/mL)
MRI brain Immunotherapy Response to
immunotherapy
Patient A 41, F FS and GTCS
Focal Epilepsy
(temporal lobe)
14 years Carbamazepine,
Lamotrigine,
Levetiracetam,
Pregabalin
1–4 FS per month Rheumatoid
arthritis, hypo-
thyroidism
>1000 Normal cell count,
protein, glucose.
CSF OCBs present
unmatched in serum
110 Reported as
normal at
time of entry
into study
IVMP then oral
prednisolone
(on MTX for RA)
No improvement.
Entered into
epilepsy surgery
programme
Patient B 41, F FS
Focal Epilepsy
(temporal lobe)
15 months Lamotrigine,
Levetriacetam,
Zonisamide
1–2 FS per month Type 1 Diabetes,
Coeliac Disease
>1000 Normal cell count,
protein, glucose.
CSF OCBs present
unmatched in serum
66 Normal IVIG for 3 months,
azathioprine
No FS for 11
months following
IVIG, but
subsequent
persistent
recurrence despite
azathioprine.
Patient also
developed optic
neuritis and
transverse myelitis.
Patient C 24, F FS and GTCS
Focal Epilepsy
(temporal lobe)
5 years Carbamazepine,
Oxcarbazepine,
Levetiracetam
4–5 FS per week None >1000 Normal cell count
and glucose.
Protein 0.52g/L. CSF
OCBs present
unmatched in serum
>200 Normal IVMP then oral
prednisolone and
azathioprine
No improvement.
Hepatotoxicity
from Azathioprine
Patient D 44, F FS and GTCS
Focal Epilepsy
(temporal lobe)
14 years Lamotrigine,
Levetiracetam,
Oxcarbazepine
1–2 FS per week Hypo-
thyroidism
>50000* Normal cell count,
protein, glucose.
CSF OCBs present
unmatched in serum
18596* Normal IVMP then oral
prednisolone
No improvement in
seizure frequency.
Cerebellar ataxia
developed during
follow up and
improved with
immunotherapy
Patient E 20, F FS and GTCS
Focal Epilepsy
(clinical focus
uncertain)
2 years Carbazmazepine,
Lamotrigine,
Clobazam
5–10 FS per week Coeliac disease,
pernicious
anaemia
>1000 Normal cell count,
protein, glucose.
CSF OCBs present
unmatched in serum
>200 Normal IVMP, Prednisolone,
IVIG, PEx.
Azathioprine
No improvement.
Patient F 42, F FS and GTCS
Focal Epilepsy
(temporal lobe)
23 years Carbamazepine,
Levetiracetam
3–4 FS per week None >1000 Normal cell count,
protein, glucose. CSF
OCBs present
unmatched in serum
with additional
matched bands found
>200 Normal None n/a
Abbreviations: AED – antiepileptic drug; FS – focal seizures; GTCS – generalised tonic clonic seizures; CSF – cerebrospinal ﬂuid; OCBs – oligoclonal bands; IVMP – intravenous methyl prednisolone; IVIG – intravenous
immunoglobulin; PEx – plasma exchange; MTX – methotrexate; RA – rheumatoid arthritis.
* Patient D was tested using the Elisa-RSR assay with different reference ranges deﬁned. The other patients were tested using the Ria-RSR assay (see Section 2).
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Table 2
Video EEG evaluation of six patients with refractory epilepsy and anti-GAD antibodies.
Interictal Semiology Ictal Seizure classiﬁcation
Patient A Left anterior temporal sharp waves De ja vu, loss of awareness,
oro-facial and upper limb automatism,
post ictal aphasia
Left anterior temporal theta Left mesial temporal
lobe epilepsy
Patient B Frequent left anterior temporal sharp
waves, occasional right temporal sharp
activity
1. De ja vu, loss of awareness (x2)
2. No aura, tonic left arm posturing (x2)
1. Left anterior temporal rhythmic delta
2. Right frontotemporal sharp waves
Multifocal epilepsy
Patient C Infrequent low amplitude right
fronto-temporal sharp waves
1. No aura, oro-facial automatisms (x2)
2. No aura, asymmetric tonic posturing
arms, left hand clonic (x1)
1. No scalp EEG changes
2. Right frontocentral (F4/C4) 6 Hz
Multifocal epilepsy
Patient D Infrequent left anterior temporal (F7)
sharp waves
No events captured n/a n/a
Patient E Slowing of background
Focal sharp waves right temporal
region
No events captured n/a n/a
Patient F Left anterior temporal sharp waves No events captured n/a n/a
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exchange and azathioprine in addition to corticosteroids. Patient C
also received azathioprine after an induction phase with corticoste-
roids. Corticosteroids were avoided in Patient B who had type 1
diabetes. In this patient, a period of induction with IVIG followed by
azathioprine were used as an alternative. IVIG was administered on a
monthly basis at a dose of 2 g/kg for 3 months. Patient A continued
on long term treatment with methotrexate throughout the study
period as part of treatment for coexisting rheumatoid arthritis.
No sustained improvement in seizure frequency was seen in any
patients receiving immunotherapy during the follow up period and
treatment reverted back to AEDs alone in all patients apart from
Patient B. This patient developed optic neuritis, and subsequently
transverse myelitis during the study period and also had a
background of type 1 diabetes and coeliac disease. Azathioprine
was continued in this patient with the presumed diagnosis of an
autoimmune inﬂammatory brain disorder. Patient D developed
cerebellar ataxia during follow up without any associated change in
seizure frequency. This patient experienced improvements in ataxia
with immunotherapy but no change in seizure frequency.
After the unsuccessful trial of immunotherapy and further
investigation after VT with FDG-PET, Patient A was entered into
the epilepsy surgery programme and underwent standard left
anterior temporal lobe resection. Post operatively the patient was
seizure free for 10 months after which occasional focal seizures
without loss of awareness occurred, up to 18 months of follow up
post operatively. Prior to surgery the patient had experienced
focal seizures with loss of awareness and generalised tonic clonic
seizures. Histological analysis of the resected specimen showed
end folium sclerosis, with no evidence of active inﬂammation.
GAD Abs have persisted in the serum at high titres following
surgery.
4. Discussion
We detected high serum titres (>1000 u/mL) of GAD Abs in 5.4%
(6/112) of patients with otherwise unexplained adult onset focal
epilepsy. These patients were also tested for antibodies directed
against the VGKC complex and to NMDA receptors, which were not
detected. CSF analysis showed the presence of intrathecal GAD Abs
as well as unmatched CSF oligoclonal bands in all patients. Four of
these patients had other autoimmune disorders. Immunotherapy
did not result in sustained improvement in seizure control in any of
our patients.
Exact comparison of prevalence data with other studies is
difﬁcult due to the use of differing arbitrary cut-off values for high
and low levels of positivity and the fact that our study only
examined patients with focal epilepsies, which appear to have ahigher prevalence of antibody positivity as compared to those with
generalised epilepsy syndromes.6 Liimatainen et al. found 2.8% of
patients they tested with refractory focal epilepsy were positive for
GAD Ab in titres (>1000 u/mL).7 In their study, Peltola et al. found
3.9% of patients in a subgroup with focal epilepsy had GAD Ab titres
>1000 u/mL.6 Our study did not have a control group. Other
studies have found only low prevalence of GAD Abs at any level in
healthy controls (0–1.5%).4,6,7
Patient A had an FDG-PET scan after VT had demonstrated
electrographic seizures arising from the left temporal lobe, which
demonstrated hypometabolism in the left temporal lobe. Retro-
spective review of the MRI scan performed prior to entry into the
study, which was reported as normal, was suggestive of
hippocampal atrophy. This patient became seizure free following
epilepsy surgery, although focal seizures without loss of awareness
have since recurred. Based on this, we feel that epilepsy surgery
should not be ruled out in patients with refractory temporal lobe
epilepsy based on the presence of GAD Abs alone.
One patient (Patient D) had cerebellar ataxia which responded
well to immunotherapy whilst the seizure control did not. Whilst
the coexistence of epilepsy and cerebellar ataxia in this patient
may simply be a chance association, this ﬁnding is of interest and
may suggest different pathological mechanisms for each disorder
given the differential response to immunotherapy. Another patient
with co-existing type 1 diabetes and coeliac disease went on to
develop optic neuritis and subsequently transverse myelitis, and
remains on long term immunosuppression for a presumed
autoimmune inﬂammatory brain disorder, perhaps indicating that
GAD Abs in this patient are simply an epiphenomenon of another
autoimmune process.
None of our patients had a sustained response to immunother-
apy and as such our experience does not support the use of
immunotherapy in patients with unexplained adult onset focal
epilepsy in whom serum or CSF GAD Abs are identiﬁed. Treatment
responses in patients with other neurological syndromes associ-
ated with GAD Ab are variable and there have been reports of
successful outcomes in stiff person syndrome,19 limbic encephali-
tis8 and epilepsy.7,11
The presence of oligoclonal bands within the CSF of patients
with LE is thought to support the notion that an autoimmune
mechanism underlies the pathogenesis of the syndrome.20 In
patients with epilepsy alone, it has been suggested that the
presence of intrathecal GAD Ab is of particular importance in
identifying patients who may respond to immunosuppression.7
The lack of improvement seen in our cohort of patients with
epilepsy who received immunosuppression, all of whom had the
presence intrathecal GAD Ab and CSF oligoclonal bands unmatched
in serum, does not support this hypothesis.
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In common with onconeural antibodies, and in contrast to the cell
surface antibodies such as those directed against the VGKC
complex or the NMDA receptor, GAD Abs are directed against
an intracellular antigen. The proposed pathogenic mechanisms of
neurological disease in patients with antibodies directed against
intracellular proteins is not clear, although may be mediated by
cytotoxic T cells, leading to inﬂammation.13,21 Inﬂammatory
changes were not demonstrated in histological specimens from
Patient A, who underwent left anterior temporal lobe resection.
Given that this patient had been experiencing seizures for 14 years
prior to antibody testing it is possible that any active autoimmune
process may have ‘‘burnt out’’. This could be consistent with the
hypothesis that an acute autoimmune illness with hippocampal
inﬂammation could lead to development of hippocampal sclerosis
and subsequent chronic temporal lobe epilepsy14,22,23 and might
explain the poor response to immunotherapy in the chronic phase.
In contrast to this, a response to immunotherapy has been
observed in patients with epilepsy and VGKC-complex antibodies
up to 2 years after onset of seizures5 possibly indicating different
pathogenic processes involved in the generation of epilepsy with
different autoantibodies.
The possibility of GAD Abs being generated as an epiphenome-
non of recurrent seizures also exists, although Brenner and
colleagues have contended that the similar prevalence of GAD
Abs found in newly diagnosed and chronic epilepsy indicates that
GAD Ab are not caused by recurrent seizures.4 One patient in our
series (patient B) went on to develop a more widespread CNS
inﬂammatory disorder, with optic neuritis and subsequently
transverse myelitis, in whom it would be reasonable to regard
the presence of GAD Ab as an epiphenomenon, acting as a marker
for an immune mediated process, rather than being a pathogenic
antibody. Other studies have demonstrated the co-existence of
GAD Abs and autoantibodies directed against neuronal surface
antigens in patients with LE, the latter of which appears more likely
to be pathogenic.11,24
Due to the retrospective design and observational method
employed, our study has a number of limitations. Antibody testing
and subsequent treatment was carried out in a clinical and
pragmatic way. The immunotherapy regimen was determined at
the discretion of the treating physician, and more potent therapies
such as cyclophosphamide were not used. We did not include a
control population and patients were not screened extensively for
co-existing neuronal autoantibodies. The patients we identiﬁed
with high positive GAD Ab titres also had a high prevalence of other
autoimmune disease, with 1 patient having type 1 diabetes. As the
presence of GAD Abs may be a manifestation of other autoimmune
disease, this factor may have contributed to the poor response of
epilepsy to immunotherapy observed in our cohort, despite the
apparent evidence of a CNS based inﬂammatory process as
suggested by the presence of intrathecal GAD Abs and oligoclonal
bands within the CSF unmatched in serum.
Systematic testing of large cohorts of epilepsy patients will be
required to identify sufﬁcient patients with autoantibodies for
further analysis and controlled trials of immunosuppressive
treatment, before any ﬁrm conclusions regarding the relevance
of autoimmunity in patients with epilepsy and GAD Abs.Conﬂicts of interests
None declared.
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